A son shared the final anniversary letter his mother wrote before Alzheimer's disease progressed, preserving a meaningful record of her earlier voice. The letter captures a personal moment, but it cannot establish when her illness began or how quickly it advanced. Alzheimer's is a progressive brain disorder that damages memory and thinking and can eventually disrupt simple tasks. It is not a normal part of aging, according to the National Institute on Aging's Alzheimer's fact sheet.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What can the final letter tell a family?
- Why can't a letter confirm Alzheimer's?
- What progression may change
- Decisions families should make early
- What approved treatments can—and cannot—mean
What can the final letter tell a family?
A letter can preserve expressions, handwriting, humor, priorities, and relationships that matter to a family. An anniversary message may become especially valuable when later changes make sustained writing or conversation difficult. However, readers should not treat wording, spelling, or handwriting as a clinical timeline.
"Final" may simply mean that no later anniversary letter exists; it does not identify a specific stage of Alzheimer's. Families sharing such material should preserve the original context. Note when it was written, who received it, and whether the person had already received a diagnosis. Avoid adding medical meaning that the letter itself cannot support.
Why can't a letter confirm Alzheimer's?
One letter, memory lapse, or family account cannot diagnose Alzheimer's. The National Institute on Aging says clinicians must assess other possible causes of cognitive changes, including some that may be treatable or reversible, as explained in its diagnosis overview. Dementia describes cognitive or behavioral loss severe enough to interfere with daily life.
More than 6 million Americans, mostly people age 65 or older, may have Alzheimer's, but each diagnosis requires an individual evaluation. A family concerned about changes should document patterns rather than relying on one emotional example. Useful notes include missed tasks, repeated questions, changes in judgment, and whether problems disrupt ordinary routines.
What progression may change
As Alzheimer's progresses, it can affect communication, recognition, and everyday tasks. Abilities do not disappear at the same pace, so a person who struggles with writing may still participate in familiar activities or express preferences. Support should match the person's current needs.
The National Institute on Aging advises caregivers to preserve independence while adding help as needed in its guidance on daily personal care. That balance may involve offering a simple choice, allowing extra response time, or helping with one step instead of taking over an entire task. Reassess support as abilities and safety needs change.
Decisions families should make early
After a dementia diagnosis, families should discuss the person's wishes while participation remains easier. The National Institute on Aging recommends early health, financial, long-term-care, and end-of-life planning in its planning checklist after a dementia diagnosis.
Start with decisions that could become difficult during a crisis: A meaningful letter may help families remember the person's values, but it does not replace formal instructions or legal documents. Planning should reflect the person's stated wishes and applicable professional guidance.
- Identify who should help with health and financial decisions.
- Record care preferences and important contacts.
- Review financial accounts, insurance, and long-term-care options.
- Store signed documents where the appropriate people can find them.
- Revisit the plan when health or living arrangements change.
What approved treatments can—and cannot—mean
The FDA granted traditional approval to Leqembi, or lecanemab, in July 2023. It is an intravenous amyloid-directed antibody studied in people with confirmed amyloid and mild cognitive impairment or mild dementia, according to the FDA approval announcement. The FDA approved Kisunla, or donanemab, in July 2024, as recorded in its approval notice.
In its phase 3 trial, donanemab slowed progression at 76 weeks, while brain swelling or fluid buildup occurred in 24.0% of recipients and 2.1% of placebo recipients, according to the published TRAILBLAZER-ALZ 2 results. These medicines slow progression in studied patients; they do not make a letter diagnostic or restore an earlier moment. Both require careful medical assessment because amyloid-related imaging abnormalities can involve brain swelling or bleeding. For Leqembi, the FDA says treatment should begin only during mild cognitive impairment or mild dementia stages.
